Inhibitory effects of T/L-type @entity460 channel blockers on tubulointerstitial @entity82 in obstructed kidneys in XXXX .

@entity8 @entity82 @entity16002 @entity101 @entity42458 @entity1369 @entity14357 @entity12614 @entity460 @entity594 @entity35 @entity2528 @entity8562
OBJECTIVES: To examine the effect of L- and T/L-type @entity460 channel blockers on interstitial @entity82 in chronic unilateral ureteral obstruction (UUO). Tubulointerstitial @entity82 is a common outcome of several progressive @entity8 . @entity460 channel blockers are widely used for the treatment of @entity101 with @entity8 ; however, the direct effect of @entity460 channel blockers on @entity8 independent of lowering blood pressure has not been fully elucidated. METHODS: @entity35 were divided into 3 treatment groups: (1) vehicle control; (2) @entity594 , an L-type @entity460 channel blockers; and (3) @entity16002 , a T/L-type @entity460 channel blockers. Treatment was initiated 1 day before and continued until 6 days after creation of the UUO. RESULTS: Tubulointerstitial @entity82 in the obstructed kidney was significantly increased compared with that in the contralateral unobstructed kidney. Furthermore, the increased @entity82 was accompanied by increased fibrogenic signaling expressed by transforming growth factor b1 and @entity2528 mRNA levels, increased oxidative stress expressed by @entity42458 , @entity12614 and @entity8562 mRNA level. Moreover, treatment with a nonhypotensive dose of @entity16002 but not @entity594 in the obstructed kidney significantly suppressed the fibrogenic signaling and the oxidative stress, resulting in reduced tubulointerstitial @entity82 . The plasma @entity1369 level in @entity16002 -treated animals was increased compared with vehicle-treated animals, although not significantly. The increased plasma @entity1369 level did not increase @entity14357 mRNA level in @entity16002 but not in @entity594 treated animals. CONCLUSIONS: Treatment with @entity16002 improved tubulointerstitial @entity82 more effectively than treatment with @entity594 in UUO. The antifibrogenic effect by @entity16002 was obtained through suppression of fibrogenic signaling.
